Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

William J. Gradishar, MD, on Triple-Negative Breast Cancer: Expert Perspective on the KEYNOTE-086 Trial Results

Posted: Wednesday, July 5, 2017

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses a phase II study of pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.